Global Partnerships Held by Celixir to Promote their Regenerative Medicines Worldwide

Celixir comes as a UK firm indulged in the discovery and development of life changing regenerative medicines and whilst working towards their common goals via collaborative partnerships. That said; let’s take a look at their collaborations with various recognized firms and institutions in the past few years.

DAIICHI SANKYO

Celixir has granted the Japan license for their innovative cardiac regeneration medicine to Daiichi Sankyo on May 2016. As per the agreement, Daiichi Sankyo will be taking care of all the development, regulatory and commercial activities regarding Celixir’s immunomodulatory progenitor cells within Japanese territory. On the other side, Celixir will be taking care of the worldwide rights for Celixir stem cells therapy for the rest of the world.

Celixir


INNOVATIVE CARDIOVASCULAR MEDICINES COLLABORATION

Celixir has further formed the Innovative Cardiovascular Medicines Collaboration which includes global experts in cardiac research and clinical development, coming onboard with a common purpose of getting a basic understanding for cardiac regeneration.

This Collaboration will be headed jointly by Professor Kim Fox, Consultant Cardiologist and Professor of Cardiology at Imperial College and Professor Sir Martin Evans celixir, who is a Nobel Laureate along with the Chief Scientific Officer of Celixir.

The same collaboration will be supported by Professor John Pepper, OBE, Interim Director of Research at the Royal Brompton and Harefield NHS Foundation Trust, together with Dr. Sabena Sultan, Global Head of Research at Celixir stem cells office.

Talking about the same collaboration, Ajan Reginald, CEO, of Celixir cell therapy, said, “Collaborations with world-class research physicians are critical in accelerating the development of innovative medicines. We’re delighted to be forming this partnership with Professors Fox and Pepper, to advance Celixir’s investigational myocardial regeneration medicine and provide future innovations that will hopefully transform patients’ lives”,

The Collaboration was formed with the key priority of investigating heart failure whilst focusing on the progressive insights into the regeneration of cardiac tissue. Same collaboration would then think about bringing all the life-saving medicines to help and support millions of heart failure patients.

TMC LIFE SCIENCES AND THOMSON MEDICAL

Celixir cell therapy has also formed collaboration with TMC Life Sciences Bhd (TMCLS) and its flagship company, Thomson Medical (Thomson) to further trigger the discovery and development of life-changing and life-altering regenerative medicines. Going by the Memoranda of Understanding (MOU), Celixir will further be developing the educational programmes to successfully train all the medical professionals in regenerative medicine with their partner hospitals (TMCLS and Thomson). On the other side, TMCLS and Thomson will be providing an access to their pan-Asia development, clinical trials and hospital network.

Comments

Post a Comment

Popular posts from this blog

Celixir’s CEO discuss about his agreement with the Japanese firm to distribute its heart failure drug

Image
Just days after the Cardiff-based cell therapy company Cell Therapy Ltd (CTL) signed an agreement with Japan’s Daiichi Sankyo, providing them with the rights to its heart failure drug Heartcel, the company’s chief executive, Ajan Reginald , got interviewed by one of the leading dailies. Heartcel, an immune-modulator progenitor (iMP), can be considered as one of the allogeneic celixir stem cells therapy which posses the power to redevelop the human heart. The same therapy has confirmed two-year MACE-free survival for all the tested patients in the Phase II clinical trial studying myocardial regeneration. As per the agreement, Daiichi Sankyo will take care of the development, regulatory approval and marketing of Heartcel in the Japanese territory, while CTL will still holds the rights for the rest of the world. Mr. Ajan Reginald , the co-founder of CTL, quoted that the deals comes as a future step towards accomplishing the global mission of bringing company’s life-saving dru
Read more

Celixir and their Collaborative Partnerships with Global Firms to Further Promote Their Regenerative Medicines Worldwide

Image
Celixir is one of the most sought after UK firms which are involved in the design and development of life changing regenerative medicines while working towards common objectives with certain collaborative partnerships. With that said, let’s take a look at some of the most talked about collaborations which Celixir has secured with some of the most recognized firms and institutions in the past decade. DAIICHI SANKYO Celixir has given the license for carrying on the marketing and distributing responsibilities of their revolutionary cardiac regeneration medicine to Daiichi Sankyo on May 2016. Going by the agreement, Daiichi Sankyo will take care for the development, regulatory and commercial activities for Celixir’s immune-modulatory progenitor cells across Japanese territory. Moreover, Celixir will still be responsible for the same operations within territories across rest of the world for Celixir stem cell therapy. INNOVATIVE CARDIOVASCULAR MEDICINES COLLABORATION Celixir has also for
Read more

Celixir announces US FDA approval of the IND application for cell therapy Heartcel

Image
Celixir announces US FDA approval of the IND application for cell therapy Heartcel FDA IND and UK MHRA CTA approval both achieved in H1 2018 Potentially pivotal heart failure trial of up to 250 patients in the UK and US Stratford-upon-Avon, UK, 08 June 2018  – Celixir, a privately owned company discovering and developing life-saving advanced therapies, announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for Heartcel its immuno-modulatory progenitor (iMP) cell therapy for the treatment of adult heart failure. Celixir announced in January the approval of a clinical trial application (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency to initiate a potentially pivotal Phase II b human clinical trial with Heartcel The international trial will recruit up to 250 patients and the IND approval allows expansion to US clinical trial sites. Ajan Reginald, Chief Executive
Read more